Rohan Faria, MD
Hematology & Oncology · Coral Springs, FLNPI 1265435077
Payments from drug & device makers
Across 174 payments — averaging $20.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Pfizer$216
- Foundation Medicine, Inc.$215
- AbbVie$186
- Astellas Pharma US Inc$142
- Novartis$137
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,21289%
- Education$39911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 81 | $1,692 |
| Pfizer | 11 | $216 |
| Foundation Medicine, Inc. | 5 | $215 |
| AbbVie | 8 | $186 |
| Astellas Pharma US Inc | 7 | $142 |
| Novartis | 8 | $137 |
| E.r. Squibb & Sons, L.L.C. | 7 | $109 |
| Eisai Inc. | 4 | $98 |
| Deciphera Pharmaceuticals Inc. | 4 | $77 |
| Servier Pharmaceuticals LLC | 3 | $70 |
| Bayer | 4 | $63 |
| Gilead | 3 | $57 |
| Aurobindo Pharma USA, Inc. | 4 | $57 |
| Adaptive Biotechnologies Corporation | 2 | $46 |
| Array Biopharma Inc | 2 | $44 |
| Incyte Corporation | 2 | $39 |
| GSK | 2 | $36 |
| Nuvation Bio Inc. | 1 | $32 |
| Daiichi Sankyo Inc. | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Coherus Oncology, Inc. | 1 | $28 |
| EMD Serono, Inc. | 1 | $27 |
| Rigel Pharmaceuticals, Inc. | 1 | $27 |
| Amgen | 1 | $26 |
| Sanofi | 1 | $23 |
| Exelixis Inc. | 1 | $22 |
| AstraZeneca | 1 | $19 |
| Tolmar Pharmaceuticals, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Octapharma USA, Inc. | 1 | $13 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $11 |
| Clovis Oncology, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,611 in reported general payments places this provider in the 35th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 63 | $967,627 |
| BrukinsaZanubrutinib | 51 | $763,549 |
| RevlimidLenalidomide | 30 | $666,122 |
| Lenalidomide | 36 | $624,133 |
| JakafiRuxolitinib Phosphate | 38 | $608,765 |
| PomalystPomalidomide | 23 | $525,295 |
| LenvimaLenvatinib Mesylate | 22 | $503,419 |
| NubeqaDarolutamide | 35 | $468,177 |
| ImbruvicaIbrutinib | 34 | $387,562 |
| TagrissoOsimertinib Mesylate | 23 | $382,121 |
| LynparzaOlaparib | 15 | $336,555 |
| VenclextaVenetoclax | 22 | $334,028 |
| VerzenioAbemaciclib | 19 | $289,812 |
| IbrancePalbociclib | 15 | $226,630 |
| ErleadaApalutamide | 12 | $177,019 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso, Lynparza | $19 | $1,686,302101 claims |
| Incyte CorporationJakafi | $39 | $608,76538 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $109 | $525,29523 claims |
| Eisai Inc.Lenvima | $98 | $503,41922 claims |
| BayerNubeqa | $63 | $468,17735 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $11 | $387,56234 claims |
| AbbVieVenclexta | $186 | $334,02822 claims |
| PfizerIbrance, Eliquis | $216 | $312,285127 claims |
| Johnson & JohnsonErleada, Xarelto | $1,692 | $234,37564 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $30 | $56147 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Coral Springs
- Carl LandgrenMiami$47.8M
- Julio ChavezTampa$16.4M
- Steven AttiaJacksonville$13.9M
- Santosh NairOrange City$13.5M
- Frederick LockeTampa$12.8M
- Tarek MekhailOrlando$11.2M
- Carlos AlemanyOrlando$10.9M
- Thomas GeorgeGainesville$10.3M
- Sikander AilawadhiJacksonville$9.8M
- Richard KimTampa$8.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.